Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006099 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00006099: Clinical Trial Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
NCT00006099 is a Phase 1 study that was terminated before completion, run by Ludwig Institute for Cancer Research. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006099, a Phase 1 study, was terminated before completion, sponsored by Ludwig Institute for Cancer Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving monoclonal antibodies in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian cancer.
Primary Outcome
All toxicities were to be graded according to the Common Toxicity Criteria (CTC) Scale, version 2.0, March 1998.The study was to be terminated upon the occurrence of an adverse event of Grade 3 or greater severity that is considered definitely related to hu3S193.
Interventions
- BIOLOGICAL Monoclonal antibody hu3S193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2000-08-02 |
| Est. Completion | 2002-08-12 |
| Phase | Phase 1 |
Why NCT00006099 stopped before completion
NCT00006099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Monoclonal antibody hu3S193 is the first listed.
NCT00006099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006099 about?
NCT00006099 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving monoclonal antibodies in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody t...
What is the current status of trial NCT00006099?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2000-08-02. Estimated completion is 2002-08-12.
What interventions are being tested in trial NCT00006099?
The interventions under investigation include: Monoclonal antibody hu3S193 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006099?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00006099's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI